[Comment] Ileal bile acid transporter inhibitors for cholestatic pruritus in primary biliary cholangitis

In medicine, treatment goals set by physicians might differ from patient priorities. Although normalisation of laboratory parameters is a target supported by outcomes data, patient perspectives regarding symptoms are often under-addressed. Primary biliary cholangitis (PBC) is a chronic, autoimmune cholangiopathy that causes liver damage in the absence of effective treatment.1 However, poor quality of life can be equally impactful, particularly regarding pruritus and fatigue,2 and a discrepancy between laboratory targets and symptomatic relief is common.